GlassScriptPhysician profile
John R Hereford
NPI 1619931557
$3,254.98
in general payments reported to CMS, 2019-2025
28 companies · $392 in 2025
The $392 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $827 · 2020: $138 · 2021: $370 · 2022: $302 · 2023: $525 · 2024: $701 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,433 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,433.18 |
| Education | $184.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $515.33 | 2022-2025 | Veozah, Myrbetriq |
| Daiichi Sankyo INC. | $358.07 | 2019-2025 | Injectafer |
| Abbvie INC. | $310.84 | 2019-2025 | |
| Pfizer INC. | $179.24 | 2019-2025 | |
| Amgen INC. | $172.99 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $159.18 | 2023-2025 | Myfembree, Gemtesa |
| Exeltis, USA INC. | $141.83 | 2022-2025 | Slynd |
| Urovant Sciences INC | $125.83 | 2022 | |
| Organon LLC | $112.02 | 2022-2024 | Nexplanon |
| Amag Pharmaceuticals, INC. | $108.22 | 2019 | |
| Dexcom, INC. | $107.40 | 2024-2025 | Dexcom G6 Transmitter |
| Mayne Pharma Commercial LLC | $105.65 | 2022-2025 | |
| Coopersurgical, INC. | $100.72 | 2021 | |
| Medical Device Business Services, INC. | $99.07 | 2019 | |
| Teleflex LLC | $93.86 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $85.34 | 2020-2023 | Balcoltra |
| Boston Scientific Corporation | $69.09 | 2025 | General - Female Sui |
| Therapeuticsmd, INC. | $68.94 | 2019 | |
| Duchesnay USA Incorporated | $64.07 | 2019 | |
| Sage Therapeutics, LLC | $55.38 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $50.99 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $42.33 | 2024-2025 | Gardasil 9, Gardasil |
| Allergan, INC. | $39.43 | 2019 | |
| Exact Sciences Corporation | $29.25 | 2025 | The Cologuard Plus Collection Kit |
| Axonics, INC. | $20.05 | 2024 | Axonics, Bulkamid |
| Hologic Sales and Service, LLC | $14.79 | 2024 | Myosure Tissue Removal Device |
| Ethicon US, LLC | $13.79 | 2019 | |
| Lupin INC. | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hereford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.